o-Aminoazotoluene
| ToxCast Endpoints |
|---|
ToxCast Endpoints for intended target type: RNA
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| LTEA_HepaRG_ABCB1 | Liver | 5243 | ABCB1 | P08183 | Inhibitory | 5.45 μM |
| LTEA_HepaRG_ABCB11 | Liver | 8647 | ABCB11 | O95342 | Inhibitory | 4.58 μM |
| LTEA_HepaRG_ABCC2 | Liver | 1244 | ABCC2 | Q92887 | Inhibitory | 3.17 μM |
| LTEA_HepaRG_ACLY | Liver | 47 | ACLY | P53396 | Inhibitory | 0.39 μM |
| LTEA_HepaRG_ACOX1 | Liver | 51 | ACOX1 | Q15067 | Inhibitory | 2.57 μM |
| LTEA_HepaRG_ADK | Liver | 132 | ADK | P55263 | Inhibitory | 4.93 μM |
| LTEA_HepaRG_AFP | Liver | 174 | AFP | P02771 | Inhibitory | 4.69 μM |
| LTEA_HepaRG_APOA5 | Liver | 116519 | APOA5 | Q6Q788 | Inhibitory | 2.97 μM |
| LTEA_HepaRG_BAX | Liver | 581 | BAX | Q07812 | Activatory | 1.99 μM |
| LTEA_HepaRG_BCL2L11 | Liver | 10018 | BCL2L11 | O43521 | Inhibitory | 3.13 μM |
| LTEA_HepaRG_CAT | Liver | 847 | CAT | P04040 | Inhibitory | 3.32 μM |
| LTEA_HepaRG_CDKN1A | Liver | 1026 | CDKN1A | P38936 | Activatory | 3.36 μM |
| LTEA_HepaRG_CFLAR | Liver | 8837 | CFLAR | O15519 | Inhibitory | 2.75 μM |
| LTEA_HepaRG_CYP1A1 | Liver | 1543 | CYP1A1 | P04798 | Activatory | 1.05 μM |
| LTEA_HepaRG_CYP2B6 | Liver | 1555 | CYP2B6 | P20813 | Inhibitory | 5.08 μM |
| LTEA_HepaRG_CYP2C19 | Liver | 1557 | CYP2C19 | P33261 | Inhibitory | 4.72 μM |
| LTEA_HepaRG_CYP2C8 | Liver | 1558 | CYP2C8 | P10632 | Inhibitory | 5.98 μM |
| LTEA_HepaRG_CYP2C9 | Liver | 1559 | CYP2C9 | P11712 | Inhibitory | 4.80 μM |
| LTEA_HepaRG_CYP3A4 | Liver | 1576 | CYP3A4 | P08684 | Inhibitory | 2.94 μM |
| LTEA_HepaRG_CYP3A5 | Liver | 1577 | CYP3A5 | P20815 | Inhibitory | 3.11 μM |
| LTEA_HepaRG_CYP3A7 | Liver | 1551 | CYP3A7 | P24462 | Inhibitory | 6.38 μM |
| LTEA_HepaRG_CYP4A11 | Liver | 1579 | CYP4A11 | Q02928 | Inhibitory | 4.52 μM |
| LTEA_HepaRG_CYP4A22 | Liver | 284541 | CYP4A22 | Q5TCH4 | Inhibitory | 4.39 μM |
| LTEA_HepaRG_FABP1 | Liver | 2168 | FABP1 | P07148 | Inhibitory | 5.03 μM |
| LTEA_HepaRG_FAS | Liver | 355 | FAS | P25445 | Activatory | 3.37 μM |
| LTEA_HepaRG_FASN | Liver | 2194 | FASN | P49327 | Inhibitory | 2.90 μM |
| LTEA_HepaRG_FMO3 | Liver | 2328 | FMO3 | P31513 | Inhibitory | 4.86 μM |
| LTEA_HepaRG_FOXO3 | Liver | 2309 | FOXO3 | O43524 | Inhibitory | 5.56 μM |
| LTEA_HepaRG_GADD45A | Liver | 1647 | GADD45A | P24522 | Activatory | 3.52 μM |
| LTEA_HepaRG_GADD45B | Liver | 4616 | GADD45B | O75293 | Inhibitory | 7.67 μM |
| LTEA_HepaRG_GADD45G | Liver | 10912 | GADD45G | O95257 | Inhibitory | 4.14 μM |
| LTEA_HepaRG_GCLC | Liver | 2729 | GCLC | P48506 | Inhibitory | 1.67 μM |
| LTEA_HepaRG_GSTA2 | Liver | 2939 | GSTA2 | P09210 | Inhibitory | 5.01 μM |
| LTEA_HepaRG_GSTM3 | Liver | 2947 | GSTM3 | P21266 | Inhibitory | 1.48 μM |
| LTEA_HepaRG_HIF1A | Liver | 3091 | HIF1A | Q16665 | Activatory | 7.09 μM |
| LTEA_HepaRG_HSPA1A | Liver | 3303 | HSPA1A | P08107 | Inhibitory | 3.55 μM |
| LTEA_HepaRG_IGF1 | Liver | 3479 | IGF1 | P05019 | Inhibitory | 4.25 μM |
| LTEA_HepaRG_IGFBP1 | Liver | 3484 | IGFBP1 | P08833 | Activatory | 9.92 μM |
| LTEA_HepaRG_IL6R | Liver | 3570 | IL6R | P08887 | Inhibitory | 2.45 μM |
| LTEA_HepaRG_LIPC | Liver | 3990 | LIPC | P11150 | Inhibitory | 3.22 μM |
| LTEA_HepaRG_LPL | Liver | 4023 | LPL | P06858 | Inhibitory | 4.40 μM |
| LTEA_HepaRG_MIR122 | Liver | 406906 | MIR122 | Inhibitory | 3.67 μM | |
| LTEA_HepaRG_MYC | Liver | 4609 | MYC | P01106 | Activatory | 5.49 μM |
| LTEA_HepaRG_NFE2L2 | Liver | 4780 | NFE2L2 | Q16236 | Activatory | 9.92 μM |
| LTEA_HepaRG_PDK4 | Liver | 5166 | PDK4 | Q16654 | Inhibitory | 2.39 μM |
| LTEA_HepaRG_PEG10 | Liver | 23089 | PEG10 | Q86TG7 | Inhibitory | 4.04 μM |
| LTEA_HepaRG_PPP2R4 | Liver | 5524 | PPP2R4 | Q15257 | Inhibitory | 2.35 μM |
| LTEA_HepaRG_PTEN | Liver | 5728 | PTEN | P60484 | Inhibitory | 4.12 μM |
| LTEA_HepaRG_SLC22A1 | Liver | 6580 | SLC22A1 | O15245 | Inhibitory | 4.83 μM |
| LTEA_HepaRG_SLCO1B1 | Liver | 10599 | SLCO1B1 | Q9Y6L6 | Inhibitory | 3.57 μM |
| LTEA_HepaRG_TGFB1 | Liver | 7040 | TGFB1 | P01137 | Activatory | 2.72 μM |
| LTEA_HepaRG_THRSP | Liver | 7069 | THRSP | Q92748 | Inhibitory | 1.41 μM |
| LTEA_HepaRG_TP53 | Liver | 7157 | TP53 | P04637 | Activatory | 1.97 μM |
| LTEA_HepaRG_XBP1 | Liver | 7494 | XBP1 | P17861 | Inhibitory | 4.00 μM |
ToxCast Endpoints for intended target type: Protein
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| CCTE_Deisenroth_AIME_384WELL_LUC_Active | Mammary Gland/Breast | 2099 | ESR1 | P03372 | Gain | 3.36 μM |
| CCTE_Deisenroth_AIME_384WELL_LUC_Inactive | Mammary Gland/Breast | 2099 | ESR1 | P03372 | Gain | 2.69 μM |
| CCTE_GLTED_hTBG | 6906 | SERPINA7 | Loss | 4.38 μM | ||
| CCTE_GLTED_hTTR_0.125uM | 7276 | TTR | Loss | 0.02 μM | ||
| ERF_TW_NR_binding_hERa | 2099 | ESR1 | P03372 | Gain | 8.41 μM | |
| NVS_ADME_hCYP1A1 | 1543 | CYP1A1 | P04798 | Loss | 5.40 μM | |
| NVS_ADME_hCYP1A2 | 1544 | CYP1A2 | P05177 | Loss | 0.86 μM | |
| NVS_ADME_hCYP2B6 | 1555 | CYP2B6 | P20813 | Loss | 1.71 μM | |
| NVS_ADME_hCYP2C19 | 1557 | CYP2C19 | P33261 | Loss | 2.69 μM | |
| NVS_ADME_hCYP2C9 | 1559 | CYP2C9 | P11712 | Loss | 4.50 μM | |
| ATG_Ahr_CIS | Liver | 196 | AHR | P35869 | Activatory | 2.99 μM |
| ATG_ERE_CIS | Liver | 2099 | ESR1 | P03372 | Activatory | 3.35 μM |
| ATG_NRF2_ARE_CIS | Liver | 4780 | NFE2L2 | Q16236 | Activatory | 7.21 μM |
| ATG_ERa_TRANS | Liver | 2099 | ESR1 | P03372 | Gain | 1.35 μM |
| BSK_3C_MCP1 | Vascular | 6347 | CCL2 | P13500 | Inhibitory | 10.76 μM |
| BSK_3C_SRB | Vascular | Inhibitory | 11.08 μM | |||
| BSK_3C_Thrombomodulin | Vascular | 7056 | THBD | P07204 | Activatory | 3.00 μM |
| BSK_3C_uPAR | Vascular | 5329 | PLAUR | Q03405 | Inhibitory | 10.40 μM |
| BSK_4H_SRB | Vascular | Inhibitory | 5.17 μM | |||
| BSK_4H_uPAR | Vascular | 5329 | PLAUR | Q03405 | Inhibitory | 1.95 μM |
| BSK_CASM3C_Thrombomodulin | Vascular | 7056 | THBD | P07204 | Activatory | 10.68 μM |
| BSK_LPS_PGE2 | Vascular | 5732 | PTGER2 | P43116 | Inhibitory | 3.97 μM |
| BSK_LPS_SRB | Vascular | Inhibitory | 9.83 μM | |||
| BSK_SAg_Eselectin | Vascular | 6401 | SELE | P16581 | Activatory | 4.75 μM |
| BSK_SAg_SRB | Vascular | Inhibitory | 9.88 μM | |||
| TOX21_AR_BLA_Antagonist_ratio | Kidney | 367 | AR | P10275 | Loss | 11.46 μM |
| TOX21_ELG1_LUC_Agonist | Kidney | 79915 | ATAD5 | Q96QE3 | Gain | 5.21 μM |
| TOX21_ERa_LUC_VM7_Agonist | Breast | 2099 | ESR1 | P03372 | Gain | 1.77 μM |
| TOX21_GR_BLA_Antagonist_ratio | Cervix | 2908 | NR3C1 | P04150 | Loss | 3.55 μM |
| TOX21_AhR_LUC_Agonist | Liver | 196 | AHR | P35869 | Gain | 1.16 μM |
| TOX21_ERR_LUC_Agonist | Kidney | 2101 | ESRRA | P11474 | Gain | 2.44 μM |
| TOX21_PGC_ERR_LUC_Agonist | Kidney | 2101 | ESRRA | P11474 | Gain | 3.46 μM |
| TOX21_PR_BLA_Antagonist_ratio | Kidney | 5241 | PGR | P06401 | Loss | 6.74 μM |
| TOX21_p450_CYP3A4_Antagonist | 1576 | CYP3A4 | P08684 | Loss | 3.21 μM | |
| TOX21_p450_CYP2C19_Antagonist | 1557 | CYP2C19 | P33261 | Loss | 7.28 μM | |
| TOX21_p450_CYP2C9_Antagonist | 1559 | CYP2C9 | P11712 | Loss | 5.02 μM | |
| TOX21_p450_CYP1A2_Antagonist | 1544 | CYP1A2 | P05177 | Loss | 1.10 μM | |
| TOX21_ERa_LUC_VM7_Agonist | Breast | 2099 | ESR1 | P03372 | Gain | 2.45 μM |
| TOX21_GR_BLA_Antagonist_ratio | Cervix | 2908 | NR3C1 | P04150 | Loss | 8.42 μM |
| TOX21_AhR_LUC_Agonist | Liver | 196 | AHR | P35869 | Gain | 2.90 μM |
| TOX21_ERR_LUC_Agonist | Kidney | 2101 | ESRRA | P11474 | Gain | 2.90 μM |
| TOX21_PGC_ERR_LUC_Agonist | Kidney | 2101 | ESRRA | P11474 | Gain | 3.76 μM |
| TOX21_p450_CYP3A4_Antagonist | 1576 | CYP3A4 | P08684 | Loss | 5.93 μM | |
| TOX21_p450_CYP2C19_Antagonist | 1557 | CYP2C19 | P33261 | Loss | 8.28 μM | |
| TOX21_p450_CYP2C9_Antagonist | 1559 | CYP2C9 | P11712 | Loss | 5.34 μM | |
| TOX21_p450_CYP1A2_Antagonist | 1544 | CYP1A2 | P05177 | Loss | 1.95 μM |
No ToxCast endpoints for intended target type: Molecular Messengers
ToxCast Endpoints for intended target type: Pathway
| Assay Name | Tissue | Target Gene ID | Target HGNC Symbol | Target UniProt ID | Response | AC50 value |
|---|---|---|---|---|---|---|
| APR_HepG2_p53Act_72hr | Liver | 7157 | TP53 | P04637 | Activatory | 2.34 μM |
| TOX21_ARE_BLA_Agonist_ch2 | Liver | Gain | 1.05 μM | |||
| TOX21_ARE_BLA_Agonist_ratio | Liver | 4780 | NFE2L2 | Q16236 | Gain | 1.44 μM |
| TOX21_AR_BLA_Antagonist_ch1 | Kidney | Gain | 10.95 μM | |||
| TOX21_HDAC_LUC_Antagonist | Colon | 3065 | HDAC1 | Q13547 | Loss | 7.80 μM |
| TOX21_ARE_BLA_Agonist_ch2 | Liver | Gain | 1.46 μM | |||
| TOX21_ARE_BLA_Agonist_ratio | Liver | 4780 | NFE2L2 | Q16236 | Gain | 2.01 μM |
| TOX21_HDAC_LUC_Antagonist | Colon | 3065 | HDAC1 | Q13547 | Loss | 7.46 μM |
ToxCast Endpoints for intended target type: Cellular
| Assay Name | Tissue | Response | AC50 value |
|---|---|---|---|
| BSK_hDFCGF_Proliferation | Skin | Inhibitory | 9.37 μM |
| LTEA_HepaRG_LDH_cytotoxicity | Liver | Loss | 5.21 μM |
| TOX21_AhR_LUC_Agonist_viability | Liver | Loss | 10.84 μM |
| TOX21_CAR_LUC_Agonist_viability | Liver | Loss | 2.07 μM |
| TOX21_CAR_LUC_Antagonist_viability | Liver | Loss | 2.52 μM |
| TOX21_CASP3_HEPG2 | Liver | Gain | 0.83 μM |
| TOX21_CASP3_HEPG2_viability | Liver | Loss | 1.73 μM |
| TOX21_AhR_LUC_Agonist_viability | Liver | Loss | 6.84 μM |
| TOX21_CAR_LUC_Agonist_viability | Liver | Loss | 0.64 μM |
| TOX21_CAR_LUC_Antagonist_viability | Liver | Loss | 0.80 μM |
| TOX21_RT_HEPG2_GLO_00hr_viability | Liver | Loss | 7.60 μM |
| TOX21_PXR_LUC_Agonist_viability | Liver | Loss | 6.62 μM |
| TOX21_CASP3_HEPG2 | Liver | Gain | 1.00 μM |
| TOX21_CASP3_HEPG2_viability | Liver | Loss | 1.26 μM |
No ToxCast endpoints for intended target type: Extracellular
DISCLAIMER
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.